Apr 26, 2016

Posted by in Biotech Stocks | 0 Comments

Trend Analysis Report: Pacific Biosciences of California (NASDAQ:PACB), Illumina Inc (NASDAQ:ILMN), Medivation Inc (NASDAQ:MDVN)

Trend Analysis Report: Pacific Biosciences of California (NASDAQ:PACB), Illumina Inc (NASDAQ:ILMN), Medivation Inc (NASDAQ:MDVN)

Pacific Biosciences of California (NASDAQ:PACB) plunged -2.99% and ended at $10.40. The total traded volume was 1.77 million shares and market capitalization arrived at $1.08 billion. The stock has a 52-week high price of $14.00 and its 52-week low was recorded at $3.58, while during last trade its minimum price was $10.02 and it gained the highest price of $10.70.

Pacific Biosciences of California (NASDAQ:PACB) on April 21, 2016 announced financial results for its first quarter ended March 31, 2016.

Revenue for the first quarter of 2016 increased by 8% to $19.1 million compared to $17.6 million for the first quarter of 2015. Product and service revenue for the first quarter of 2016 was $15.5 million, compared to $14.0 million for the first quarter of 2015. Revenue for the first quarter of each of 2016 and 2015 reflected $3.6 million of contractual revenue amortization from the upfront Roche payment pursuant to the Roche agreement.

Gross profit increased by $3.6 million to $9.5 million for the first quarter of 2016, resulting in a gross margin of 49.7%, compared to gross profit of $5.9 million and a gross margin of 33.6% for the first quarter of 2015. The growth in gross profit and margin was primarily driven by the higher margin sales of the company’s SequelTM System which was launched in the fourth quarter of 2015.

Operating expenses for the first quarter of 2016 totaled $28.1 million, compared to $25.3 million for the first quarter of 2015. Operating expenses for the first quarter of 2016 and 2015 included non-cash stock-based compensation of $4.1 million and $3.0 million, respectively.

Net loss for the first quarter of 2016 was $19.4 million, compared to $20.2 million for the first quarter of 2015.

Cash and investments at March 31, 2016 totaled $91.5 million, compared to $82.3 million at December 31, 2015.

Illumina Inc (NASDAQ:ILMN) reported the decrease of -0.36% to close at $143.07 with the overall traded volume of 1.70 million shares. Its market capitalization on last close reached to $20.84 billion. Its beta value stands at 0.84 times. The company has the total of 147.08 million outstanding shares. Its intraday-low price was $142.47 and its hit its day’s highest price at $144.47.

Illumina Inc (NASDAQ:ILMN) on April 18, 2016 announced that results for first fiscal quarter 2016 will be issued following the close of market on Tuesday, May 3, 2016. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jay Flatley, Chairman and CEO, Francis deSouza, President, and Marc Stapley, Executive Vice President, Chief Administrative Officer, and Chief Financial Officer, will host a conference call to discuss financial and operating results.

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

Medivation Inc (NASDAQ:MDVN) moved down -1.08% to settle at $52.07. Its total traded volume during last trading session was 1.65 million shares. The overall market worth of this company is about $8.44 billion. The 52 week range of the stock remained $26.41 – $66.90, while its day’s lowest price was $51.80 and its hit its day’s highest price at $52.94. The beta of this stock currently stands at 1.38.

Medivation Inc (NASDAQ:MDVN) on April 21, 2016 announced that it will host a live teleconference with management to discuss first quarter 2016 financial results and provide a general business update on May 5, 2016 at 4:30 p.m. Eastern Time. A press release for the first quarter 2016 will be released after markets close on May 5, 2016.

Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families.

 

Comments are closed.